{"schema_version":"secwatch.filing_event.v1","accession":"0001562762-23-000208","form_type":"8-K","ticker":"GMED","cik":"0001237831","company_name":"GLOBUS MEDICAL INC","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.203401+00:00","generated_at":"2026-06-15T20:45:39.211026+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Globus Medical Q1 net sales up 20% to $276.7M; non-GAAP EPS $0.53","bullets":["Worldwide net sales $276.7M, up 20% YoY (21% constant currency); GAAP net income $49.1M.","GAAP diluted EPS $0.48; non-GAAP diluted EPS $0.53, up 24.7% YoY.","U.S. Spine sales up 14%; Enabling Technologies grew 91% to $25M.","Full-year 2023 guidance reaffirmed: net sales $1.1B, non-GAAP diluted EPS $2.30.","Pending merger with NuVasive received shareholder approvals from both companies."],"urls":{"canonical":"https://secwatch.observer/filing/0001562762-23-000208","json":"https://secwatch.observer/filing/0001562762-23-000208.json","markdown":"https://secwatch.observer/filing/0001562762-23-000208.md","text":"https://secwatch.observer/filing/0001562762-23-000208.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1237831/000156276223000208/0001562762-23-000208-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1237831/000156276223000208/gmed-20230504x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T20:45:39.211026+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"909c9740e196c5c004a296201e9ac7a8a4ed1435","claim":"GLOBUS MEDICAL INC reported three-month period ended March 31, 2023 results: revenue $276.7 million, net income $49.1 million, EPS $0.48.","evidence_excerpt":"· Worldwide net sales were $276.7 million , an increase of 20.0% , or 21.0% on a constant currency basis · GAAP net income for the quarter was $49.1 million · GAAP d iluted earnings per share (“ EPS ”) was $0.48","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1237831/000156276223000208/0001562762-23-000208-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three-month period ended March 31, 2023"},{"label":"Revenue","value":"$276.7 million"},{"label":"Net income","value":"$49.1 million"},{"label":"EPS","value":"$0.48"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}